Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Psychiatry Research. Neuroimaging|May 2, 2026
Brain iron-sensitive markers (magnetic susceptibility and R2*) predict antidepressant response to ketamine in treatment-resistant depressionKengo Yonezawa, Shinichiro Nakajima, Shuhei Shibukawa, et al.
Schizophrenia (Heidelberg, Germany)|June 2, 2026
Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025Yoshiteru Takekita, Hideaki Tani, Yasushi Kawamata, et al.
Brain Imaging and Behavior|November 2, 2023
Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medicationHideaki Tani, Iska Moxon-Emre, Natalie J Forde, et al.
Pharmacopsychiatry|July 7, 2026
Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled TrialKie Nomoto, Yohei Ohtani, Taisuke Yatomi, et al.
BMC Psychiatry|November 19, 2013
Melancholic and reactive depression: a reappraisal of old categoriesJin Mizushima, Hitoshi Sakurai, Yuya Mizuno, et al.
Psychiatry and Clinical Neurosciences|August 30, 2024
Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trialYohei Ohtani, Hideaki Tani, Kie Nomoto-Takahashi, et al.
Molecular Psychiatry|April 21, 2022
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatmentMasataka Wada, Yoshihiro Noda, Yusuke Iwata, et al.
Cell Reports. Medicine|April 20, 2023
Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsyTsuyoshi Eiro, Tomoyuki Miyazaki, Mai Hatano, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2026
Age and sex-dependent alteration in AMPA receptor density in living human brainMai Hatano, Waki Nakajima, Shohei Tsuchimoto, et al.
Molecular Psychiatry|March 4, 2026
The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depressionWaki Nakajima, Mai Hatano, Yohei Ohtani, et al.
Pageof 6